Dermatological Therapeutics Market, By Application (Alopecia, Herpes, Psoriasis, Rosacea, Atopic Dermatitis, and Other Applications), By Drug Class (Anti-infectives, Corticosteroids, Anti-acne, Calcineurin Inhibitors, Retinoids and Other Drug Classes) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI483121 | Publish Date: May 2024 | No. of Pages: 180

Global Dermatological Therapeutics Market Companies

  • GI Dermatics
  • Allergan Inc
  • Amgen Inc
  • Chester Valley Pharmaceuticals Inc
  • Dermik Laboratories Inc
  • Eisai Inc.
  • Ferndale Laboratories Inc.
  • Genentech Inc.
  • Medicis Pharmaceutical Corp
  • Onset Therapeutics
  • Prime Pharmaceuticals Corp
  • Schering-Plough Corp
  • Sinclair Pharmaceutical
  • Skinmedica Inc.
  • Summers Laboratories Inc
  • Valeant Pharmaceuticals International

Recent News:

  • In December 2021, LEO Pharma Inc. announced that the US FDA has approved Adbry (tralokinumab-ldrm) for the treatment of moderate to severe atopic dermatitis in adults 18 years of age and older whose disease is not adequately controlled with topical therapies. Prescription or when these methods are not adequately controlled.
  • In December 2021, the US FDA approved the expanded use of Amgen Inc.'s drug Otezla to treat adults with mild to moderate plaque psoriasis.
  •  In September 2021, Incyte announced that the US FDA approved Opzelura cream (ruxolitinib)  for the short-term, chronic, intermittent treatment of mild to moderate atopic dermatitis (AD) in  patients not immunocompromised 12 years of age or older whose disease is not adequately controlled by prescription topical therapies or when these therapies are not recommended.